Corina Loghin

1.6k total citations · 2 hit papers
21 papers, 1.2k citations indexed

About

Corina Loghin is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Corina Loghin has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Corina Loghin's work include Diabetes Treatment and Management (14 papers), Metabolism, Diabetes, and Cancer (6 papers) and Pharmacology and Obesity Treatment (5 papers). Corina Loghin is often cited by papers focused on Diabetes Treatment and Management (14 papers), Metabolism, Diabetes, and Cancer (6 papers) and Pharmacology and Obesity Treatment (5 papers). Corina Loghin collaborates with scholars based in United States, Germany and Singapore. Corina Loghin's co-authors include Shweta Urva, Xuewei Cui, Tamer Coşkun, Charles Benson, Daniel A. Briere, Axel Haupt, William C. Roell, Kyle W. Sloop, Ruth E. Gimeno and Julie S. Moyers and has published in prestigious journals such as Circulation, Cell Metabolism and Diabetes.

In The Last Decade

Corina Loghin

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

2018 603 citations Tamer Coşkun, Kyle W. Sloop et al. Molecular Metabolism profile →
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

2022 180 citations Tamer Coşkun, Shweta Urva et al. Cell Metabolism profile →

Peers

Countries citing papers authored by Corina Loghin

Since Specialization

Citations

This map shows the geographic impact of Corina Loghin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corina Loghin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corina Loghin more than expected).

Fields of papers citing papers by Corina Loghin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corina Loghin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corina Loghin. The network helps show where Corina Loghin may publish in the future.

Co-authorship network of co-authors of Corina Loghin

This figure shows the co-authorship network connecting the top 25 collaborators of Corina Loghin. A scholar is included among the top collaborators of Corina Loghin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corina Loghin. Corina Loghin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept breakdown → 2022 ·Cell Metabolism ·Tamer Coşkun, Shweta Urva, William C. Roell, Hongchang Qu, Corina Loghin, Julie S. Moyers, Libbey S. O′Farrell, Daniel A. Briere, Kyle W. Sloop, Melissa K. Thomas, Valentina Pirro, David B. Wainscott, Francis S. Willard, (unknown), LaRonda L. Morford, Yu Du, Charles Benson, Ruth E. Gimeno, Axel Haupt, Zvonko Miličević	180
2	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide 2021 ·Clinical Pharmacokinetics ·Shweta Urva, Tonya Quinlan, John Landry, Jennifer A. Martin, Corina Loghin	41
3	Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study 2021 ·Advances in Therapy ·(unknown), Yifei Zhang, Yiming Li, Xia Zhao, Weiwei Zhou, Corina Loghin, Lai Tham, Xuewei Cui, Yimin Cui, Weiqing Wang	7
4	Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide 2021 ·Diabetologie und Stoffwechsel ·Shweta Urva, Tonya Quinlan, John Landry, Jennifer A. Martin, Corina Loghin, (unknown)	1
5	104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects 2021 ·Diabetes ·Shweta Urva, Yu Du, Melissa K. Thomas, Zvonko Miličević, Tamer Coşkun, Charles Benson, Corina Loghin	4
6	106-OR: A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects 2021 ·Diabetes ·(unknown), Melissa K. Thomas, Charles Benson, Ross Bray, (unknown), Corina Loghin	1
7	The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists 2020 ·Diabetes Obesity and Metabolism ·Shweta Urva, Tamer Coşkun, Corina Loghin, Xuewei Cui, (unknown), Libbey S. O′Farrell, Daniel A. Briere, Charles Benson, Michael A. Nauck, Axel Haupt	92
8	971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide 2020 ·Diabetes ·Shweta Urva, Tonya Quinlan, John Landry, Jennifer C. Martin, Corina Loghin	1
9	Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion 2019 ·CPT Pharmacometrics & Systems Pharmacology ·Bridget L. Morse, (unknown), Maria M. Posada, Jessica Rehmel, (unknown), Lai Tham, Corina Loghin, Kathleen M. Hillgren, Stephen D. Hall, Gemma L. Dickinson	25
10	58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist 2019 ·Diabetes ·Shweta Urva, Michael A. Nauck, Tamer Coşkun, Xuewei Cui, Axel Haupt, Charles Benson, Corina Loghin	2
11	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept breakdown → 2018 ·Molecular Metabolism ·Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, (unknown), Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt	603
12	No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide 2017 ·Clinical Pharmacokinetics ·Amparo de la Peña, Xuewei Cui, (unknown), Corina Loghin	17
13	Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials 2015 ·Clinical Pharmacokinetics ·(unknown), Michael Heathman, Xuewei Cui, Jennifer A. Martin, Corina Loghin, Jenny Y. Chien, Amparo de la Peña	75
14	Abstract #252: Once Weekly Dulaglutide may be Coadministered with Warfarin Without Dose Adjustment 2015 ·Endocrine Practice ·Amparo de la Peña, Corina Loghin, Xuewei Cui	1
15	Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis 2015 ·Journal of Clinical Densitometry ·John H. Krege, David L. Kendler, Kelly Krohn, Harry K. Genant, Jahangir Alam, Pierre‐Yves Berclaz, Barbara J. Coffey, Corina Loghin	46
16	Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers 2012 ·British Journal of Clinical Pharmacology ·Corina Loghin, Harry Haber, Charles M. Beasley, Prajakti A. Kothare, (unknown), (unknown), Ling Jin, Albert J. Allen, Malcolm I. Mitchell	11
17	Systematic Decrements in QTc between the First and Second Day of Contiguous Daily ECG Recordings under Controlled Conditions 2011 ·Pacing and Clinical Electrophysiology ·Charles M. Beasley, Charles Benson, (unknown), S. Stanley Young, Harry Haber, Malcolm I. Mitchell, Corina Loghin	0
18	Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women 2008 ·Clinical Pharmacokinetics ·Evelyn D. Lobo, Corina Loghin, Mary Pat Knadler, Tonya Quinlan, Lu Zhang, Jill Chappell, Richard Lucas, Richard F. Bergstrom	35
19	Pharmacokinetic evaluation of combined duloxetine and fluvoxamine dosing in CYP2D6 poor metabolizers 2005 ·Clinical Pharmacology & Therapeutics ·D. S. Small, Corina Loghin, Ruth Lucas, Mary Pat Knadler, (unknown), Jill Chappell, Richard Bergstrom, John T. Callaghan	7
20	Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles 2004 ·Circulation ·(unknown), P. R. Bieck, Emily M. Garland, Corina Loghin, Frank P. Bymaster, Bonnie K. Black, Celedon Gonzales, William Z. Potter, David W. Robertson	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact